The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1668
January 23, 2023
View Complete Issue         Table of Contents 2019 
Topical Roflumilast (Zoryve) for Plaque Psoriasis
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Topical Roflumilast (Zoryve) for Plaque Psoriasis
January 23, 2023 (Issue: 1668)
The FDA has approved a 0.3% cream formulation of the phosphodiesterase-4 (PDE4) inhibitor roflumilast (Zoryve – Arcutis) for topical treatment of plaque psoriasis in patients ≥12 years old. Roflumilast is the first topical PDE4 inhibitor to...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Topical Roflumilast (Zoryve) for Plaque Psoriasis
Article code: 1668b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.